Replies to post #205 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Hopefully, there will be additional trials as not only do a number of studies show an association between higher frequencies of TAMs and poor prognosis across different types, but also they can mediate therapeutic resistance.

The clinical data from OR2805 (+/- an anti-PD-1, chemo, or an anti-EGFR) will be interesting as well https://jitc.bmj.com/content/9/Suppl_2/A294